You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.

This drug entry is a stub and has not been fully annotated. It was added on September 23, 2015 and is scheduled to be annotated soon.

NamePotassium Citrate
Accession NumberDB09125
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent.

IndicationFor the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
Structure
Thumb
Synonyms
SynonymLanguageCode
tripotassium citrateNot AvailableNot Available
Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet, extended release10 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet5 meq/1OralUpsher Smith Laboratories2006-09-01Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release1080 mg/1OralPhysicians Total Care, Inc.2006-07-24Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet10 meq/1OralUpsher Smith Laboratories2006-09-01Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralAmerincan Health Packaging2014-10-01Not applicableUs
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Urocit KTablet, extended release540 mgOralMission Pharmacal1995-01-01Not applicableCanada
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal1985-09-01Not applicableUs
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal1992-09-01Not applicableUs
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal2010-01-27Not applicableUs
Urocit-KTablet, extended release10 meq/1OralRemedy Repack2016-12-27Not applicableUs
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUs
Urocit-KTablet, extended release1080 mgOralMission Pharmacal2011-02-11Not applicableCanada
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
B6 Plus TabVita Health Products Inc
Cytra-K CrystalsCypress Pharmaceuticals, Inc.
Formula No. 2 Plus K LiqGolden Pride/Rawleigh
LytrenMead Johnson Nutritionals
Lytren Rhs LiqMead Johnson Nutritionals
Potassium Citrate and Citric AcidPharmaceutical Associates, Inc.
Potassium Citrate Citric Acid CrystalsVirtus Pharmaceuticals
Potassium Citrate-citric AcidMethod Pharmaceuticals
Potassium Citrate-sodium Citrate-citric AcidMethod Pharmaceuticals
RehydralyteRoss Laboratories, Division Of Abbott Laboratories Ltd.
TricitratesPharmaceutical Associates, Inc.
SaltsNot Available
CAS numberNot Available
WeightAverage: 306.394
Monoisotopic: 305.89464697
Chemical FormulaC6H5K3O7
InChI KeyQEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
Drug Interactions
Drug
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium Citrate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium Citrate.
Aluminum hydroxidePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium Citrate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium Citrate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium Citrate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium Citrate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium Citrate.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium Citrate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium Citrate.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium Citrate.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium Citrate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium Citrate.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium Citrate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium Citrate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium Citrate.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Potassium Citrate.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium Citrate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.
External Links
ReferencesNot Available
Comments
comments powered by Disqus
Drug created on September 23, 2015 10:41 / Updated on January 20, 2017 09:39